9 September 2022
EMA/CVMP/721187/2022
Committee for Veterinary Medicinal Products

Summary of opinion[1] (post-authorisation)

Improvac

Common name: gonadotropin releasing factor analogue diphtheria toxoid conjugate

On 08 September 2022, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Improvac. The marketing authorisation holder for this veterinary medicinal product is Zoetis Belgium SA.

Improvac is currently authorised for administration to female pigs from 14 weeks of age onwards with 2 doses of 2 ml administered approximately 4 weeks apart. The variation concerns the extension of the inter-dose interval from 4 to 8 weeks, and to reduce the minimum age of vaccination accordingly (from 14 to 10 weeks of age) in female pigs. The additional variation is to update the product information according to QRD template version 9.0.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union